Ovarian Cancer Subtypes May Predict Response to Bevacizumab

Sean Dowdy, M.D., a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. For more information